Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

Andrew Blauvelt,May Venturanza,Jonathan Silverberg,Kang Sun,Michael Kuligowski,Lawrence Eichenfeld

doi:10.25251/skin.5.supp.65

Abstract

N/A

Highlights

Long-Term Safety and Disease Control With Ruxolitinib Cream Among Patients With Atopic Dermatitis Based on Previous Medication History: Pooled Results From Two Phase 3 Studies
● Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itching, dryness, and redness[1]
● Some topical treatments may be insufficient because of inadequate efficacy, delayed onset of efficacy, duration-of-use limitations, anatomic use restrictions, poor tolerability, and/or adverse reactions1,2 – topical corticosteroids (TCS) are associated with decreased skin thickness and elasticity; they are not recommended for long-term application or use in sensitive areas – topical calcineurin inhibitors (TCI) are associated with local reactions, such as stinging and burning

Summary

Introduction

● Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itching, dryness, and redness[1]. ● Treatments for AD include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and systemic immunomodulatory agents[1]. ● Some topical treatments may be insufficient because of inadequate efficacy, delayed onset of efficacy, duration-of-use limitations, anatomic use restrictions, poor tolerability, and/or adverse reactions1,2 – TCS are associated with decreased skin thickness and elasticity (eg, striae); they are not recommended for long-term application or use in sensitive areas – TCI are associated with local reactions, such as stinging and burning. ● Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and JAK23. ● In two phase 3 randomized studies of identical design (TRuE-AD1 [NCT03745638] and TRuE-AD2 [NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD3

Study Design and Patients

Results

Disclosures